Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Natera, Quest Diagnostics, Sophia Genetics, More

NEW YORK – Natera said this week that it has filed a pre-submission to the US Food and Drug Administration for its Panorama noninvasive prenatal test, following publication of the results of the SMART trial. The company filed its pre-submission in June for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome. 

Sophia Genetics this week filed a $200 million preliminary shelf registration with the US Securities and Exchange Commission. This would be Sophia's first stock offering since it raised $234 million in an initial public offering in July 2021. The Swiss-American company also reported its Q2 financial results this week. 

Quest Diagnostics this week announced a quarterly cash dividend of $.66 per share, payable on Oct. 19 to shareholders of record as of Oct. 4. 

Chinese molecular testing company Health Gene Technologies said this week that it has completed a Series C financing of “hundreds of millions” of Chinese yuan. The round was led by Shenzhen Capital Group, with additional investments from BioTrack Capital, Ningbo Hefeng Venture Capital, Ningbo Yingong Venture Capital Partnership, and Ningbo Binjiang Xin Cheng Development Investment. Health Gene said the funding will primarily be used for new technology research and product development. Founded in August 2011, Health Gene Technologies, based in Ningbo, China, has developed and commercialized nucleic acid testing products for forensic science and precision medicine. 

Todos Medical said this week that its CLIA-certified, CAP-accredited laboratory Provista Diagnostics has entered into contracts to provide PCR-based monkeypox testing services. One deal is with an unnamed New Jersey-based medical group that specializes in dermatologic screening. The second agreement is an expansion of an existing deal with an unnamed New Jersey-based CLIA-certified lab that already included COVID-19 testing. Other terms of the deals were not disclosed. Provista's saliva-based monkeypox test is being developed as a laboratory-developed test. 

Applied DNA said this week that it has closed its previously announced public offering of 3 million shares of its common stock, together with Series A warrants to purchase up to another 3 million shares and Series B warrants to buy up to 3 million more shares at a combined offering price of $4 per share and associated warrants. Gross proceeds totaled $12 million before agent's fees and other offering expenses. Separately, the company said that it received about $3.6 million in net proceeds following an exercise of Series B warrants from the offering by an institutional investor. H.C. Wainwright acted as the exclusive placement agent for the offering. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.